Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

One-Third of Americans Now Use AI for Health Advice — and Many Are Skipping the Doctor

by Team Lumida
March 31, 2026
in Health and Longevity
Reading Time: 4 mins read
A A
0
One-Third of Americans Now Use AI for Health Advice — and Many Are Skipping the Doctor
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways

  • Roughly 1 in 3 U.S. adults have used AI to find health information, with nearly 30% seeking physical health advice and 1 in 6 turning to AI for mental health questions — making AI as common a health resource as social media, according to a new KFF poll of more than 1,300 adults.
  • More than 40% of health AI users have uploaded personal medical data — including test results and doctor’s notes — into AI tools, even as more than three-quarters of all adults say they are very or somewhat concerned about health data privacy.
  • About 1 in 5 AI health users cited inability to get an appointment or lack of a provider as a major driver — signaling that AI is increasingly filling access-to-care gaps rather than simply supplementing routine medical consultations.
  • Younger adults and low-income individuals are most likely to use AI for health questions and least likely to follow up with a provider afterward — raising concerns that AI may be widening rather than bridging healthcare equity gaps.

What Happened?

A new poll from KFF, the nonpartisan health policy research organization, finds that approximately one-third of U.S. adults have used AI tools to seek health information — a level of adoption that now rivals social media as a source of health guidance. The survey, conducted among more than 1,300 adults, found that 29% had used AI for physical health information in the past year and 1 in 6 had used it for mental health queries. The most cited reason for using AI was the desire for quick health advice, followed by researching information before a doctor’s visit. However, a significant minority — about 1 in 5 users — said they turned to AI specifically because they lacked a provider or couldn’t secure an appointment, underlining AI’s growing role as a substitute for, not just a supplement to, professional medical care. The poll also found that about 6 in 10 adults who used AI for physical health advice subsequently saw a doctor, and 4 in 10 sought a mental health professional — but younger adults were considerably less likely to make that follow-up visit.

Why It Matters?

For investors in healthcare AI and digital health, the KFF poll provides some of the most concrete market sizing data yet for the consumer health AI category. OpenAI, Microsoft, and Amazon have all launched health-specific AI tools in recent months, betting on exactly this kind of mass adoption. The 40%-plus rate of personal medical data uploads into AI tools is particularly significant: it suggests consumers are already treating these platforms as quasi-medical record repositories, creating both a competitive moat for the platforms that capture this data and a serious regulatory risk as the FTC, HHS, and state attorneys general scrutinize AI health data practices. The finding that younger, lower-income users are most likely to use AI as a primary — not supplementary — healthcare resource raises important equity and liability questions. If AI health tools give misleading or incomplete advice to populations that are least likely to follow up with a clinician, the public health consequences could be significant and the legal exposure for AI companies could be material.

What’s Next?

The health AI market is accelerating on multiple fronts simultaneously. OpenAI’s health-specific ChatGPT launched in January, Microsoft’s dedicated health AI chatbot followed in March, and Amazon expanded its health-focused AI assistant the same month — suggesting the competitive intensity will only increase. Regulatory clarity, however, is lagging: the FDA has begun scrutinizing AI clinical decision support tools but has not yet established clear standards for consumer-facing health AI. The data privacy concern flagged by KFF — more than 75% of adults worried about personal health data in AI systems — is a regulatory flashpoint that could trigger HIPAA-adjacent legislation if a major data breach occurs. For investors evaluating healthcare AI plays, the key metrics to watch are not just user numbers but follow-up care conversion rates, data upload penetration, and whether platforms can monetize the health data they’re collecting without triggering a regulatory or reputational crisis.


Source: https://www.healthcaredive.com/news/kff-poll-ai-health-information-adults/744217/

Previous Post

The Iran War’s Invisible Casualty: A Helium Crisis That Could Cripple AI Chips and MRI Scanners

Next Post

Wall Street Just Wrapped Its Worst Quarter in Four Years — and Investors Are Bracing for Worse

Recommended For You

Weight-Loss Drugs Like Ozempic May Also Slow Cancer — Four New Studies Show Striking Results

by Team Lumida
4 days ago
Eli Lilly and Novo Nordisk Shares Plunge Amid Ozempic Vision Loss Fears

GLP-1 drugs used for diabetes and obesity are linked to reduced tumor progression, lower cancer mortality, and decreased breast cancer risk across hundreds of thousands of patients in...

Read more

GLP-1 Weight-Loss Drugs Are Triggering Rapid Muscle Loss — and Doctors Are Sounding the Alarm

by Team Lumida
1 week ago
GLP-1 Weight-Loss Drugs Are Triggering Rapid Muscle Loss — and Doctors Are Sounding the Alarm

As 13 million Americans take GLP-1 drugs like Ozempic and Mounjaro, a growing body of research warns the drugs can cause up to 10% lean muscle loss —...

Read more

Hospital at Home Linked to Lower Mortality and Fewer ER Visits, JAMA Study Finds

by Team Lumida
2 weeks ago
dextrose hanging on stainless steel IV stand

A new JAMA Network Open study of Medicare data shows hospital-at-home programs reduce in-hospital mortality, ED visits, and ICU escalations — but adoption is concentrated in urban hospitals...

Read more

8 Evidence-Based Tips for Healthy Eating, According to the NHS

by Team Lumida
2 weeks ago
vegetable salad

From starchy carbs to salt limits, the UK's National Health Service lays out the practical fundamentals of a balanced diet — and most adults are still getting it...

Read more

The FDA Is Fast-Tracking Psychedelics. The Infrastructure to Support Them Isn’t Ready.

by Team Lumida
3 weeks ago
Abstract colorful psychedelic swirling patterns

Trump's executive order to accelerate psychedelic drug development is welcome — but Bloomberg Opinion's Lisa Jarvis warns the ketamine clinic free-for-all is a cautionary tale the FDA must...

Read more

Ultrasound on a Chip: Butterfly Network’s $4,000 Device Is Taking Medical Imaging Global

by Team Lumida
4 weeks ago
a person holding a tablet

Butterfly Network's semiconductor-based handheld ultrasound costs a fraction of traditional machines and has reached 150,000 deployments worldwide, pairing AI with imaging to put diagnostics in the hands of...

Read more

Nearly 1 in 8 Americans Now Uses Sleep Aids — and Pharma Is Taking Notice

by Team Lumida
4 weeks ago
woman sleeping on bed under blankets

A new federal study finds 13% of U.S. adults rely on prescription drugs, OTC supplements, marijuana, or CBD to sleep, as Eli Lilly's $7.8B acquisition of a sleep...

Read more

Amazon One Medical Launches GLP-1 Weight Loss Program at $25 a Month

by Team Lumida
4 weeks ago
Amazon Targets Rural America: A Game-Changer for Delivery Services

Amazon One Medical is rolling out a weight management program that includes GLP-1 medications, offering compounded pills starting at $25/month with same-day delivery in 3,000 cities.

Read more

Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses

by Team Lumida
1 month ago
Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses

Melatonin is generally safe for short-term use and non-habit-forming, but it carries real side effects and drug interactions that most users overlook — Mayo Clinic breaks down what...

Read more

How Much Muscle Should You Have — and What Happens When You Lose It?

by Team Lumida
1 month ago
diagram

Muscle mass averages, why they matter for long-term health, and what the science says about measuring and building skeletal muscle across every age group.

Read more
Next Post
AI Job-Loss Panic Is Running Ahead of the Data, Says Bloomberg Opinion

Wall Street Just Wrapped Its Worst Quarter in Four Years — and Investors Are Bracing for Worse

McCormick to Buy Unilever’s $15.7B Food Empire in a Deal That Reshapes the Global Pantry

McCormick to Buy Unilever's $15.7B Food Empire in a Deal That Reshapes the Global Pantry

Related News

China’s Central Bank Embraces Hedge Fund Tactics to Tame $4 Trillion Bond Market

Trump’s China Tariff Order Threatens $800 De Minimis Trade Exemption, Rattling E-commerce Giants

February 6, 2025
GLP-1 Weight-Loss Drugs Are Triggering Rapid Muscle Loss — and Doctors Are Sounding the Alarm

GLP-1 Weight-Loss Drugs Are Triggering Rapid Muscle Loss — and Doctors Are Sounding the Alarm

May 18, 2026
Whirlpool Cuts Dividend and Lowers Full-Year Profit Guidance Amid Tariff Pressures

Whirlpool Cuts Dividend and Lowers Full-Year Profit Guidance Amid Tariff Pressures

July 29, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018